Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | AHR | P35869 | 4/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.46 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.46 |
| ▸ | ITGAL | P20701 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | ADK | P55263 | 1/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.42 |
| ▸ | CMA1 | P23946 | 1/20 | 0.40 |
| ▸ | TYR | P14679 | 1/20 | 0.40 |
| ▸ | CCNC | P24863 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29465576 | 1.00 | — | — | |
| SCHEMBL12470 | 1.00 | — | — | |
| SCHEMBL27728878 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL5532283 | 0.98 | MAPT (0.49) | MAPTAHRTRPA1CA1CA2 | |
| Hydrochloric Acid SCHEMBL2978417 | 0.98 | MAPT (0.49) | MAPTAHRTRPA1CA1CA2 | |
| SCHEMBL7491548 | 0.98 | MAPT (0.49) | MAPTAHRTRPA1CA1CA2 | |
| Bromide SCHEMBL1242434 | 0.98 | MAPT (0.49) | MAPTAHRTRPA1CA1CA2 | |
| SCHEMBL17372872 | 0.92 | MAPT (0.45) | MAPTAHRTRPA1CA1CA2 | |
| Formic Acid SCHEMBL23291890 | 0.88 | CCNC (0.44) | MAPTAHRTRPA1CA1CA2 | |
| Sulfuric Acid SCHEMBL3830347 | 0.88 | MAPT (0.43) | MAPTAHRTRPA1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11369624-B2 | Salts of prodrugs of piperazine and substituted piperidine antiviral agents | VIIV HEALTHCARE UK (NO. 4) LIMITED | 2022-06-28 | — | — | US | disclosed |
| US-20210023098-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK NO 4 LTD (GB) | 2021-01-28 | — | — | US | disclosed |
| US-20200046743-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK NO 4 LTD (GB) | 2020-02-13 | — | — | US | disclosed |
| US-20190111066-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK NO 4 LTD (GB) | 2019-04-18 | — | — | US | disclosed |
| US-20180000849-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK (NO 4) LTD (GB) | 2018-01-04 | — | — | US | disclosed |
| US-9655888-B2 | Tricyclic alkene derivatives as HIV attachment inhibitors | VIIV Healthcare UK (No.5) Limited (GB) | 2017-05-23 | — | — | US | disclosed |
| EP-2696937-B1 | THIOAMIDE, AMIDOXIME AND AMIDRAZONE DERIVATIVES AS HIV ATTACHMENT INHIBITORS | VIIV HEALTHCARE UK (NO 5) LTD (GB) | 2017-05-17 | — | — | EP | disclosed |
| US-9586957-B2 | 2-keto amide derivatives as HIV attachment inhibitors | VIIV Healthcare UK (No.5) Limited (GB) | 2017-03-07 | — | — | US | disclosed |
| US-20160361328-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK (NO 4) LTD (GB) | 2016-12-15 | — | — | US | disclosed |
| US-9505752-B2 | Piperidine amide derivatives as HIV attachment inhibitors | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2016-11-29 | — | — | US | disclosed |
| CN-1688311-A | Compositions and antiviral activity of substituted azaindoloxoacetylpiperazine derivatives | BRISTOL MYERS SQUIBB CO (US) | 2005-10-26 | — | — | CN | disclosed |
| US-20050209246-A1 | Prodrugs of piperazine and substituted piperidine antiviral agents | SALZUFER HOLDING INC., AS ADMINISTRATIVE AGENT | 2005-09-22 | — | — | US | disclosed |
| CN-1671697-A | Indoles, azaindoles and related heterocyclic 4-alkenyl piperidine amides | BRISTOL MYERS SQUIBB CO (US) | 2005-09-21 | — | — | CN | disclosed |
| US-20050124623-A1 | For example, 2-(4-Benzoyl-piperazin-1-yl)-3-(4-chloro-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-3-oxo-propionitrile; useful for the treatment of HIV and AIDS | SILEO, LLC | 2005-06-09 | — | — | US | disclosed |
| CN-1612763-A | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | BRISTOL MYERS SQUIBB CO (US) | 2005-05-04 | — | — | CN | disclosed |
| US-20050075364-A1 | Indole, azaindole and related heterocyclic N-substituted piperazine derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2005-04-07 | — | — | US | disclosed |
| EP-1474135-A1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC PYRROLIDINE DERIVATIVES | Bristol-Myers Squibb Company (US) | 2004-11-10 | — | — | EP | disclosed |
| US-20040186292-A1 | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2004-09-23 | — | — | US | disclosed |
| WO-2004011425-A2 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC UREIDO AND THIOUREIDO PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-05 | — | — | WO | disclosed |
| WO-2003068221-A1 | INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC PYRROLIDINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000849-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | MAPT 4639/4885AHR 1714/4885TRPA1 1679/4885 |
| US-20190111066-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | MAPT 4639/4885AHR 1714/4885TRPA1 1679/4885 |
| US-20050075364-A1 | Indole, azaindole and related heterocyclic N-substituted piperazine derivatives | IDO2, IDO1, INMT | MAPT 3872/4885AHR 185/4885TRPA1 2837/4885 |
| US-20050209246-A1 | Prodrugs of piperazine and substituted piperidine antiviral agents | ZC3HAV1L, CCR5, CCRL2 | MAPT 4583/4885AHR 1096/4885TRPA1 1531/4885 |
| US-20040186292-A1 | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides | IDO1, IDO2, INMT | MAPT 3614/4885AHR 176/4885TRPA1 3386/4885 |
| US-20210023098-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | ZC3HAV1L, CCR5, CCRL2 | MAPT 4573/4885AHR 1759/4885TRPA1 1354/4885 |
| US-11369624-B2 | Salts of prodrugs of piperazine and substituted piperidine antiviral agents | CCR5, ZC3HAV1L, CCRL2 | MAPT 4639/4885AHR 1714/4885TRPA1 1679/4885 |
| US-20200046743-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | MAPT 4639/4885AHR 1714/4885TRPA1 1679/4885 |
| US-20160361328-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | MAPT 4639/4885AHR 1714/4885TRPA1 1679/4885 |
| US-20050124623-A1 | For example, 2-(4-Benzoyl-piperazin-1-yl)-3-(4-chloro-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-3-oxo-propionitrile; useful for the treatment of HIV and AIDS | CD4, CCR5, PAICS | MAPT 4057/4885AHR 1354/4885TRPA1 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.